ATLANTA, April 1, 2015 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today the appointment of Jean F. Holloway to the position of Vice President, General Counsel and Corporate Secretary effective April 1, 2015. Ms. Holloway will report directly to Pat Mackin, President and Chief Executive Officer.
Mr. Mackin commented, "Jean is tremendously talented and has extensive legal experience in the medical device industry. We believe that her knowledge and background in our sector will further strengthen our team as we execute on our four growth strategies: new products, global expansion, new indications and business development."
Previously, Ms. Holloway was Dean and Professor of Law at Hamline University, School of Law in St. Paul, MN. Additionally, she was of counsel at Dorsey & Whitney and a strategic advisor to the firm's Healthcare Industry Practice Group. Prior to that, she held various executive management roles in the medical device industry, most recently as Vice President, General Counsel and Secretary for C.R. Bard, Inc., as Vice President, Deputy General Counsel at Medtronic, Inc., and as Vice President, CRM Litigation at Boston Scientific and Guidant Corp. Earlier, Ms. Holloway was a Partner at Dorsey & Whitney, worked for McKinsey & Company, and was a partner at Faegre & Benson. Ms. Holloway holds two Bachelor of Arts degrees from Yale University and earned both her MBA and JD from the University of Chicago.
About CryoLife, Inc.
CryoLife, Inc. is a leader in medical device manufacturing and distribution and in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries. It operates throughout the U.S. and internationally. CryoLife manufactures and distributes BioGlue® Surgical Adhesive, an FDA-approved adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in Europe for use in soft tissue repair and has received additional marketing approvals in several other countries throughout the world. CryoLife's BioFoam® Surgical Matrix is CE marked in Europe for use as an adjunct to hemostasis in cardiovascular surgery and on abdominal parenchymal tissues (liver and spleen) when control of bleeding by ligature or conventional methods is ineffective or impractical. CryoLife distributes PerClot®, a powdered hemostat, in Europe and other select international countries. CryoLife is conducting a pivotal clinical trial in the U.S. for potential FDA approval of the surgical version of PerClot. CryoLife specializes in the treatment of coronary artery disease for severe angina using a laser console system and single-use, fiber-optic handpieces to perform a surgical procedure known as Transmyocardial Revascularization (TMR). CryoLife markets the HeRO® Graft, which is a solution for end-stage renal disease in certain hemodialysis patients. CryoLife distributes ProCol®, a natural biological graft derived from a bovine mesenteric vein that provides vascular access for end-stage renal disease hemodialysis patients, which is approved for sale in the U.S. CryoLife also distributes PhotoFixTM Decellularized Bovine Pericardium, a proven, clinically effective tissue substitute that has undergone a dye-mediated photo-oxidation fixation process, is biocompatible without toxicity, and is derived from bovine pericardium, a material known for reliable consistency and strength with handling characteristics similar to autologous pericardium. CryoLife's CryoValve® SG pulmonary heart valve, processed using CryoLife's proprietary SynerGraft® technology, has FDA 510(k) clearance for the replacement of diseased, damaged, malformed, or malfunctioning native or prosthetic pulmonary valves. CryoLife's CryoPatch® SG pulmonary cardiac patch has FDA 510(k) clearance for the repair or reconstruction of the right ventricular outflow tract (RVOT), which is a surgery commonly performed in children with congenital heart defects.
For additional information about the company, visit CryoLife's website:
http://www.cryolife.com.
Contacts: |
|
CryoLife |
The Ruth Group |
D. Ashley Lee |
Nick Laudico / Zack Kubow |
Executive Vice President, Chief Financial Officer |
646-536-7030 / 7020 |
and Chief Operating Officer |
|
Phone: 770-419-3355 |
Logo - http://photos.prnewswire.com/prnh/20140319/MM86518LOGO
SOURCE CryoLife, Inc.
Share this article